Mediclinic Middle East and its Swiss sister company, Hirslanden, have announced the launch of their first-ever collaborative clinical trial. The groundbreaking project, led by Dr Annett Hamadi, Principal Investigator and Consultant General and Breast Surgeon at Mediclinic City Hospital in Dubai, aims to determine the effectiveness of chemotherapy performed before tumour surgery in breast cancer patients. The trial will investigate whether imaging and intelligent vacuum-assisted biopsy of tissue can predict a complete remission, potentially allowing some patients to avoid surgery. The study will involve 420 patients in the UAE, Switzerland, Austria, and Germany, and will continue until the end of 2025.
Dr Hamadi emphasized the significance of this collaboration, stating that working together with their sister division in Switzerland provides access to a larger patient pool and leverages the combined knowledge and expertise of both countries. She hopes that the results of the trial will improve treatment strategies and outcomes for breast cancer patients.
Mediclinic Middle East is known for its advanced cancer diagnosis and treatment services, including two Comprehensive Cancer Centres in Dubai and Abu Dhabi. These centres, built in collaboration with Hirslanden, offer patients the opportunity to benefit from the exchange of knowledge between experts in Europe and the Middle East, as well as access to the latest treatment programs and technology.
I have over 10 years of experience in the field of cryptocurrency and blockchain technology. I have attended numerous conferences and events around the world, and my work has been featured in major publications such as CoinDesk, Bitcoin Magazine, and Yahoo Finance.
